22 October 2016 - The Transparency Committee, responsible for evaluating medicinal products within the High Authority of Health recommended against four medicines prescribed against the symptoms of Alzheimer’s disease.

On 19 October 2016, the Transparency Commission, in charge of Medicines in the High Authority for Health (HAS) has given its opinion: four drugs still widely prescribed against Alzheimer’s disease have a service medical rendered insufficient. In other words, these experts see them as unnecessary and asking the government to stop their refund. It is Ebixa, Aricept, Exelon and of Reminyl, all referred to symptomatic. 

The information revealed by our colleagues Liberation , was confirmed to us by the Transparency Commission. “The report reflecting this opinion will be issued within seven days of its pronunciation, so by October 26, 2016 ” we did it indicates. The opinions of the Transparency Committee is advisory and it is the Ministry of Health to take the decision of delisting. An important measure – that France would be the first country to take – given the impact of this disease, which affects more than 850,000 people in France.

Read Stopru article